1. Wiszniewski, Wojciech, Fondaneche, Marie-Claude, Louise-Plence, Pascale, Fischer, Alain, Lisowska-Grospierre, Barbara. 2003. Novel mutations in the RFXANK gene: RFX complex containing in-vitro-generated RFXANK mutant binds the promoter without transactivating MHC II. In Immunogenetics, 54, 747-55. doi:. https://pubmed.ncbi.nlm.nih.gov/12618906/
2. Abolnezhadian, Farhad, Dehghani, Razieh, Dehnavi, Sajad, Khodadadi, Ali, Shohan, Mojtaba. . A novel mutation in RFXANK gene and low B cell count in a patient with MHC class II deficiency: a case report. In Immunologic research, 68, 225-231. doi:10.1007/s12026-020-09141-9. https://pubmed.ncbi.nlm.nih.gov/32578129/
3. Lennon-Duménil, A M, Barbouche, M R, Vedrenne, J, Dellagi, K, Alcaïde-Loridan, C. . Uncoordinated HLA-D gene expression in a RFXANK-defective patient with MHC class II deficiency. In Journal of immunology (Baltimore, Md. : 1950), 166, 5681-7. doi:. https://pubmed.ncbi.nlm.nih.gov/11313409/
4. Cai, Yu Qing, Zhang, HangHu, Wang, Xiang Zhi, Shu, YingYing, Tang, Lan Fang. 2020. A Novel RFXANK Mutation in a Chinese Child With MHC II Deficiency: Case Report and Literature Review. In Open forum infectious diseases, 7, ofaa314. doi:10.1093/ofid/ofaa314. https://pubmed.ncbi.nlm.nih.gov/32875002/
5. Forsberg, Jeremy, Li, Xinge, Akpinar, Birce, Zhivotovsky, Boris, Olsson, Magnus. 2018. A caspase-2-RFXANK interaction and its implication for MHC class II expression. In Cell death & disease, 9, 80. doi:10.1038/s41419-017-0144-y. https://pubmed.ncbi.nlm.nih.gov/29362422/
6. Alharby, Essa, Obaid, Mona, Elamin, Mohammed A O, Alasmari, Ali, Almontashiri, Naif A M. 2021. Progressive Ataxia and Neurologic Regression in RFXANK-Associated Bare Lymphocyte Syndrome. In Neurology. Genetics, 7, e586. doi:10.1212/NXG.0000000000000586. https://pubmed.ncbi.nlm.nih.gov/33855173/
7. Mousavi Khorshidi, Mohadese Sadat, Seeleuthner, Yoann, Chavoshzadeh, Zahra, Shahrooei, Mohammad, Parvaneh, Nima. 2023. Clinical, Immunological, and Genetic Findings in Iranian Patients with MHC-II Deficiency: Confirmation of c.162delG RFXANK Founder Mutation in the Iranian Population. In Journal of clinical immunology, 43, 1941-1952. doi:10.1007/s10875-023-01562-z. https://pubmed.ncbi.nlm.nih.gov/37584719/
8. Naamane, Hamid, El Maataoui, Ouafaa, Ailal, Fatima, Saile, Rachid, Bousfiha, Ahmed Aziz. 2010. The 752delG26 mutation in the RFXANK gene associated with major histocompatibility complex class II deficiency: evidence for a founder effect in the Moroccan population. In European journal of pediatrics, 169, 1069-74. doi:10.1007/s00431-010-1179-6. https://pubmed.ncbi.nlm.nih.gov/20414676/
9. Gulec Koksal, Zeynep, Bilgic Eltan, Sevgi, Topyildiz, Ezgi, Karakoc Aydiner, Elif, Baris, Safa. 2024. MHC Class II Deficiency: Clinical, Immunological, and Genetic Insights in a Large Multicenter Cohort. In The journal of allergy and clinical immunology. In practice, 12, 2490-2502.e6. doi:10.1016/j.jaip.2024.06.046. https://pubmed.ncbi.nlm.nih.gov/38996837/
智鼠故事 
